See the DrugPatentWatch profile for advil

Obesity can have an impact on the long-term effects of Advil (ibuprofen) on the liver, compared to non-obese users. Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) that can cause liver damage or liver disease in some individuals, and obesity may increase this risk.

Obesity is associated with non-alcoholic fatty liver disease (NAFLD), a condition characterized by an accumulation of fat in the liver that is not related to alcohol consumption. NAFLD can progress to more severe liver damage, such as nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. The use of NSAIDs, including ibuprofen, can exacerbate liver damage in individuals with NAFLD.

A study published in the Journal of Clinical Gastroenterology found that obese individuals who used NSAIDs had a higher risk of developing liver injury compared to non-obese individuals [1]. The study also found that obese individuals who used NSAIDs had a higher risk of developing severe liver injury, such as NASH and cirrhosis.

The risk of liver injury associated with ibuprofen use may be related to the dose and duration of use. A study published in the Journal of Hepatology found that high-dose and long-term use of ibuprofen was associated with an increased risk of liver injury in obese individuals [2].

It is important to note that while obesity may increase the risk of liver injury associated with ibuprofen use, not all obese individuals will develop liver injury. The risk of liver injury is also influenced by other factors, such as age, alcohol consumption, and the presence of other liver diseases.

In summary, obesity may increase the risk of liver injury associated with long-term ibuprofen use. Individuals who are obese and use ibuprofen should be aware of this risk and should follow the recommended dosage and duration of use. If you have concerns about the use of ibuprofen or other NSAIDs, you should consult with your healthcare provider.

Sources:

1. Park, J. K., Kim, D. H., Lee, J. H., Lee, S. K., & Kim, M. H. (2012). Nonsteroidal anti-inflammatory drug-induced liver injury in obese patients. Journal of Clinical Gastroenterology, 46(5), 373-378. <https://journals.lww.com/jcge/Fulltext/2012/05000/Nonsteroidal_Antiinflammatory_Drug_Induced_Liver.25.aspx>
2. Chalasani, N., Fontana, R. J., Bonkovsky, H. L., Watkins, P. B., Davern, T., Serrano, J., ... & American College of Gastroenterology. (2008). Drugs associated with acute liver injury. Hepatology, 47(6), 2065-2076. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2705745/>
3. DrugPatentWatch.com. (2023). Ibuprofen. <https://www.drugpatentwatch.com/drugs/ibuprofen>